← Human Trials & Peer-Reviewed Studies
Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial.
Plain-language guide to PMID 36587225 (2022): single-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 75 patients.
Key Facts
- PMID
- 36587225
- Journal
- BMC complementary medicine and therapies
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Jadidi A et al. (4 authors)
- DOI
- 10.1186/s12906-022-03814-8
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Restless legs syndrome/Willis-Ekbom Disease (RLS/WED) is one of the most prevalent sleep disorders.
Who Took Part
The abstract describes 75 patients taking part.
Randomly, 75 patients were assigned into three groups: magnesium, vitamin B6, and placebo.
Patients' disease severity and sleep quality were evaluated three times using standard questionnaires (at the beginning of the study, one and two months after therapy).
How the Study Was Run
The design is described as randomized, single-blind and placebo-controlled.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In this single-blind Vitamin D, K2, Magnesium and Zinc study one party knew the assignments and the other did not.
Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
While others in the control group merely received a placebo.
Utilizing SPSS22 software and the ANOVA, t-test, and repeated measure tests, statistical analysis was conducted.
What Was Measured
Topics PubMed links to this paper include Magnesium, Restless Legs Syndrome, Vitamin B 6 and Surveys and Questionnaires.
The authors tagged it with the keywords Pramipexole, Sleep disorders, Vitamin B6 and Willis-Ekbom Disease.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 75 patients.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (BMC complementary medicine and therapies), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.